Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

SC vs IV pembrolizumab: Which route is better for metastatic NSCLC?
30 Apr 2025
bởiStephen Padilla
In patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), subcutaneous (SC) pembrolizumab (pembro) demonstrates comparable efficacy to that of intravenous (IV) pembro as regards overall exposure and trough concentration, reports a study presented at ELCC 2025.
30 Apr 2025








